Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by TMAN2019on Dec 18, 2019 10:23am

116 Views

Post# 30467908

RE:RE:RE:Every f... day red

Unfortunately there is no interest in the stock, volume is low

part of it tax selling but in my opinion investors are waiting for warrant conversion

once we get some financial news sp will either go up if positive if not we wait and see game,

I don't expect anything to happen until 2nd week of January. Hopefully some retail investor will maximize their TFSA but will be low nothing big

wait and see for RVX as always I don't expect a Christmas miracle from DM!

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023